By Sherri Oslick —

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Eisai R &
D Management Co., Ltd. v. Honorable David J. Kappos
1:12-cv-01138;
filed October 12, 2012 in the Eastern District of Virginia

Review and
correction of the patent term adjustment calculation made by the U.S. Patent
and Trademark Office for U.S. Patent No. 8,158,620 ("Fused
Aminodihydrothiazine Derivatives," issued April 17, 2012).  View the complaint here.

Genetic
Technologies Ltd. v. Genetics & IVF Institute, Inc.
3:12-cv-00724;
filed October 11, 2012 in the Eastern District of Virginia

Infringement
of U.S. Patent No. 5,612,179 ("Intron Sequence Analysis Method for
Detection of Adjacent Locus Alleles as Haplotypes," issued March 18, 1997)
based on Genetics & IVF Institute's manufacture, use, sale, and offer for
sale of preimplantation genetic diagnosis services.  View the complaint here.

Purdue Pharma
LP et al. v. Sandoz Inc.
1:12-cv-07582;
filed October 10, 2012 in the Southern District of New York

• Plaintiffs: 
Purdue Pharma LP; Grunenthal GmbH
• Defendant: 
Sandoz Inc.

Infringement
of U.S. Patent No. 8,114,383 ("Abuse-Proofed Dosage Form," issued
February 14, 2012 following a Paragraph IV certification as part of Sandoz's
filing of an ANDA to manufacture a generic version of Purdue Pharma's
OxyContin® (controlled release oxycodone hydrochloride, used to treat
pain).  View the complaint here.